All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
FDA approves pirtobrutinib for patients with relapsed/refractory CLL/SLL
By Sabina Ray
On December 1, 2023, it was announced that the U.S. Food and Drug Administration (FDA) had approved pirtobrutinib, a selective non-covalent Bruton’s tyrosine kinase inhibitor (BTKi), for the treatment of adult patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) after ≥2 lines of therapy, including a B-cell lymphoma 2 inhibitor and BTKi. This decision is based on promising overall response and duration of response rates from the phase I/II BRUIN (NCT03740529).1
BRUIN trial
BRUIN is a phase I/II open-label study evaluating pirtobrutinib in patients with R/R CLL/SLL.1 The Lymphoma Hub previously reported the trial design and promising results (Figure 1).
Figure 1. BRUIN trial outcomes in patients with R/R CLL/SLL (n = 108)*
ORR, overall response rate.
*Adapted from PR Newswire.1
Conclusion
The approval of pirtobrutinib provides patients with R/R CLL/SLL another treatment option that could potentially benefit their patient journey.
- PR Newswire. Jaypirca® (pirtobrutinib) now approved by U.S. FDA for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have rreceived at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. https://www.prnewswire.com/news-releases/jaypirca-pirtobrutinib-now-approved-by-us-fda-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-who-have-received-at-least-two-lines-of-therapy-including-a-btk-inhibitor-and--302003695.html. Published Dec 1, 2023. Accessed Dec 4, 2023.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
6 votes - 53 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox